ALX Oncology Announces Upcoming Investor Conference Participation

Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO) is participating in four investor conferences to discuss its immuno-oncology therapies targeting the CD47 checkpoint pathway. Key events include the Credit Suisse 31st Annual Healthcare Conference on November 9, Stifel 2022 Healthcare Conference on November 15, Jefferies London Healthcare Conference on November 17, and Piper Sandler 34th Annual Healthcare Conference on November 29. The company is focused on the clinical development of its lead product candidate, evorpacept, aimed at treating various cancers.

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in four upcoming investor conferences.

Credit Suisse 31st Annual Healthcare Conference
Format: Formal presentation
Date: Wednesday, November 9
Time: 9:50 AM Pacific Time/ 12:50 PM Eastern Time
Location: Rancho Palos Verdes, CA
Webcast link: Available here

Stifel 2022 Healthcare Conference
Format: Fireside chat with analyst, Bradley Canino
Date: Tuesday, November 15
Time: 3:00 PM Eastern Time
Location: New York, NY
Webcast link: Available here

Jefferies London Healthcare Conference
Format: Fireside chat with analyst, Michael Yee
Date: Thursday, November 17
Time: 2:40 PM Greenwich Mean Time/ 9:40 AM Eastern Time
Location: London, UK
Webcast link: Available here

Piper Sandler 34th Annual Healthcare Conference
Format: Fireside chat with analyst, Chris Raymond
Date: Tuesday, November 29
Time: 9:00 AM Eastern Time
Location: New York, NY
Webcast link: Will be made available on ALX Oncology website

A live webcast of the presentation and fireside chats can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcasts will be archived for up to 90 days following the presentation and fireside chat dates.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.

FAQ

What investor conferences is ALX Oncology participating in November 2022?

ALX Oncology is participating in the Credit Suisse 31st Annual Healthcare Conference, Stifel 2022 Healthcare Conference, Jefferies London Healthcare Conference, and Piper Sandler 34th Annual Healthcare Conference.

When is the Credit Suisse 31st Annual Healthcare Conference for ALX Oncology?

The Credit Suisse 31st Annual Healthcare Conference is on November 9, 2022, at 9:50 AM Pacific Time.

What is the focus of ALX Oncology's lead product candidate, evorpacept?

Evorpacept is focused on blocking the CD47 checkpoint pathway to treat hematologic and solid tumors.

Where can I find the webcasts for ALX Oncology's presentations?

Webcasts can be accessed on ALX Oncology's website under the Investors section.

What time is ALX Oncology's presentation at the Stifel 2022 Healthcare Conference?

The presentation at the Stifel 2022 Healthcare Conference is scheduled for November 15, 2022, at 3:00 PM Eastern Time.